

Maja Ludvigsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/42763/publications.pdf>

Version: 2024-02-01

54
papers

606
citations

759233

12
h-index

677142

22
g-index

56
all docs

56
docs citations

56
times ranked

1131
citing authors

#	ARTICLE	IF	CITATIONS
1	IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load. <i>Haematologica</i> , 2022, 107, 877-886.	3.5	5
2	Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling. <i>Cancers</i> , 2022, 14, 247.	3.7	2
3	CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus. <i>Leukemia and Lymphoma</i> , 2022, , 1-5.	1.3	0
4	Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 460-465.	2.4	4
5	Immunophenotypically defined stem cell subsets in paediatric <scp>AML</scp> are highly heterogeneous and demonstrate differences in <scp>BCL</scp> expression by cytogenetic subgroups. <i>British Journal of Haematology</i> , 2022, 197, 452-466.	2.5	2
6	Tumor-Tissue Expression of the Hyaluronic Acid Receptor RHAMM Predicts Histological Transformation in Follicular Lymphoma Patients. <i>Cancers</i> , 2022, 14, 1316.	3.7	4
7	Exploring dyserythropoiesis in patients with myelodysplastic syndrome by imaging flow cytometry and machine learning assisted morphometrics. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 554-567.	1.5	10
8	PD-1 Expression in Pre-Treatment Follicular Lymphoma Predicts the Risk of Subsequent High-Grade Transformation. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 481-489.	2.0	9
9	Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2021, 13, 398.	3.7	16
10	Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2502-2506.	3.5	8
11	Coexisting BRAF-Mutated Langerhans Cell Histiocytosis and Primary Myelofibrosis with Shared JAK2 Mutation. <i>Case Reports in Hematology</i> , 2021, 2021, 1-5.	0.4	4
12	Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies. <i>European Journal of Haematology</i> , 2021, 107, 81-91.	2.2	6
13	Proteomic Characterization of Colorectal Cancer Tissue from Patients Identifies Novel Putative Protein Biomarkers. <i>Current Issues in Molecular Biology</i> , 2021, 43, 1043-1056.	2.4	2
14	Intratatumoral expression of CD38 in patients with post-transplant lymphoproliferative disorder. <i>Acta Oncologica</i> , 2021, 60, 1637-1642.	1.8	2
15	Imaging flow cytometry reveals a subset of TdT negative TALL blasts with very low forward scatter on conventional flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, , .	1.5	1
16	Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia. <i>Cancers</i> , 2021, 13, 5526.	3.7	3
17	High intratumoural galectin-1 expression predicts adverse outcome in ALK+ ALCL and CD30+ PTCL-NOS. <i>Hematological Oncology</i> , 2020, 38, 59-66.	1.7	6
18	Unraveling clonal heterogeneity at the stem cell level in myelodysplastic syndrome: In pursuit of cell subsets driving disease progression. <i>Leukemia Research</i> , 2020, 92, 106350.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Proteomic Characterization of Colorectal Cancer Cells versus Normal-Derived Colon Mucosa Cells: Approaching Identification of Novel Diagnostic Protein Biomarkers in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3466.	4.1	26
20	Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. <i>Haematologica</i> , 2020, 105, 2432-2439.	3.5	16
21	Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort. <i>Leukemia and Lymphoma</i> , 2020, 61, 2584-2594.	1.3	11
22	Towards identification of novel putative biomarkers for infective endocarditis by serum proteomic analysis. <i>International Journal of Infectious Diseases</i> , 2020, 96, 73-81.	3.3	10
23	Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post autologous stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 885-892.	5.2	33
24	Glycolytic biomarkers predict transformation in patients with follicular lymphoma. <i>PLoS ONE</i> , 2020, 15, e0233449.	2.5	9
25	Clonal Hematopoiesis Drives Therapy-Related Myeloid Neoplasms Following Autologous Stem Cell Transplantation and Propagates during Disease Evolution. <i>Blood</i> , 2020, 136, 15-16.	1.4	1
26	Perturbations of urea cycle enzymes during posthepatectomy rat liver failure. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G429-G440.	3.4	1
27	High intratumoral expression of vimentin predicts histological transformation in patients with follicular lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 35.	6.2	11
28	Shared Genomic Alterations in Patients with Co-Existing Myeloproliferative Neoplasms and Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2776-2776.	1.4	1
29	Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study. <i>Blood Advances</i> , 2018, 2, 1562-1571.	5.2	10
30	Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified. <i>Blood Advances</i> , 2018, 2, 2533-2542.	5.2	8
31	Therapy-Related Myeloid Neoplasms Following Autologous Stem Cell Transplantation: The Prevalence of Chip Mutations at Time of Transplantation – a Single Center Experience. <i>Blood</i> , 2018, 132, 1529-1529.	1.4	0
32	Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. <i>Leukemia</i> , 2017, 31, 83-91.	7.2	87
33	Diurnal expression of proteins in the retina of the blind cone rod homeobox (<i>Crx</i> ^{+/+}) mouse and the 129/Sv mouse: a proteomic study. <i>Acta Ophthalmologica</i> , 2017, 95, 717-726.	1.1	6
34	Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma. <i>Aids</i> , 2017, 31, 2311-2313.	2.2	2
35	MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2017, 7, 654.	6.2	26
36	High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome. <i>Blood Advances</i> , 2017, 1, 1427-1439.	5.2	37

#	ARTICLE	IF	CITATIONS
37	Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1977-1982.	2.0	13
38	Monoclonal B-cell lymphocytosis; not the same as B-cell chronic lymphocytic leukaemia. <i>Danish Medical Journal</i> , 2017, 64, .	0.5	0
39	Proteomic profiling of pretreatment serum from HIV-infected patients identifies candidate markers predictive of lymphoma development. <i>Aids</i> , 2016, 30, 1889-1898.	2.2	5
40	A systematic review of biomarkers in the diagnosis of infective endocarditis. <i>International Journal of Cardiology</i> , 2016, 202, 564-570.	1.7	27
41	Upfront Rituximab Maintenance after Induction Therapy Improves Outcome and Reduces the Risk of Histological Transformation in Patients with Follicular Lymphoma - Real World Data from a Danish Population-Based Cohort. <i>Blood</i> , 2016, 128, 1783-1783.	1.4	0
42	Low Serum Galectin-1 Levels Predict Future Lymphoma Development in HIV-Positive Patients. <i>Blood</i> , 2016, 128, 2945-2945.	1.4	0
43	High Intratumoral Expression of Galectin-1 Correlates with Superior Outcome in HIV-Associated DLBCL. <i>Blood</i> , 2016, 128, 4142-4142.	1.4	0
44	Differential protein expression of peroxiredoxinâ€1 in classical Hodgkin Lymphoma: a possible correlation to clinical behaviour. <i>Hematological Oncology</i> , 2015, 33, 253-255.	1.7	2
45	Relationship of intratumoural protein expression patterns to age and Epstein-Barr virus status in classical Hodgkin lymphoma. <i>European Journal of Haematology</i> , 2015, 95, 137-149.	2.2	8
46	Serum Proteomic Changes after Randomized Prolonged Erythropoietin Treatment and/or Endurance Training: Detection of Novel Biomarkers. <i>PLoS ONE</i> , 2015, 10, e0117119.	2.5	6
47	Fibulin-1C, C1 Esterase Inhibitor and Glucose Regulated Protein 75 Interact with the CREC Proteins, Calumenin and Reticulocalbin. <i>PLoS ONE</i> , 2015, 10, e0132283.	2.5	5
48	Proteomic approaches to the study of malignant lymphoma: Analyses on patient samples. <i>Proteomics - Clinical Applications</i> , 2015, 9, 72-85.	1.6	9
49	Melanoma tumors frequently acquire LRP 2 /megalin expression, which modulates melanoma cell proliferation and survival rates. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 267-280.	3.3	30
50	Histologically transformed follicular lymphoma exhibits protein profiles different from both non-transformed follicular and de novo diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2015, 5, e293-e293.	6.2	10
51	Proteomic Analysis of Tissue from β 1,3-galactosyltransferase Knockout Mice Reveals That a Wide Variety of Proteins and Protein Fragments Change Expression Level. <i>PLoS ONE</i> , 2013, 8, e80600.	2.5	6
52	Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 6638-6649.	1.4	79
53	Identification and characterization of novel ERCC5 interacting proteins: Evidence for the existence of several ERCC5 splicing variants; including the cytosolic ERCC5. <i>Proteomics</i> , 2009, 9, 5267-5287.	2.2	16
54	Identification and characterization of endonuclein binding proteins: evidence of modulatory effects on signal transduction and chaperone activity. <i>BMC Biochemistry</i> , 2009, 10, 34.	4.4	5